- Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)
(PAR-25-322)
Office of the Director, NIH
National Center for Complementary and Integrative Health
National Cancer Institute
National Eye Institute
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Environmental Health Sciences
National Institute of Mental Health
National Institute on Minority Health and Health Disparities
National Institute of Nursing Research
National Library of Medicine
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
Office of Research on Women's Health
The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this notice of funding opportunity (NOFO) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
Aging Mammalian Tissues In Vitro (R21 Clinical Trial Not Allowed)
(RFA-AG-26-014)
National Institute on Aging
This notice of funding opportunity (NOFO) invites applications that propose interdisciplinary research that aims to develop complex mammalian 3-dimensional (3D) in vitro microphysiological systems (MPS) to model aging and recapitulate aging processes/phenotypes observed in the whole organism in vivo. This NOFO is primarily focused on human cell-derived MPS (e.g., tissue chip, organ-on-chip, tissue organoids). However, systems developed using cells of nonhuman mammalian origin are acceptable for benchmarking, system validation, or when their relevance to understanding human aging biology is justified. Supported projects will be expected to advance the adoption of MPS in aging biology research and as new human-relevant tools for drug discovery.
Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Disease (R01 Clinical Trial Not Allowed)
(RFA-AI-25-022)
National Institute of Allergy and Infectious Diseases
The purpose of this notice of funding opportunity (NOFO) is to solicit research applications focused on preclinical development of lead candidate vaccines to prevent Mycobacterium tuberculosis (Mtb) infection and/or disease, and to increase the clinical pipeline of viable vaccine candidates.
Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)
(RFA-OD-25-008)
National Institutes of Health
National Cancer Institute
National Heart, Lung, and Blood Institute
National Institute on Drug Abuse
This Notice of Funding Opportunity (NOFO) aims to support new biomedical, behavioral, and social science investigators who are in the early stages of establishing independent careers in tobacco regulatory research. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies, secondary analysis of existing data, small, self-contained research projects, development of research methodology, and development of new research technology. Applicants are encouraged to conduct projects that ultimately have the potential to inform regulations on tobacco product manufacturing, distribution, and marketing. Research projects must address one or more High-Priority Research Topic(s) related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31.
The awards under this NOFO will be administered by NIH using funds made available through FDA CTP and the FSPTCA. Research results from this NOFO are expected to generate findings and data directly relevant to informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
Single Source: National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) (U24 Clinical Trial Not Allowed)
(RFA-AG-26-002)
National Institute on Aging
This is a non-competitive funding opportunity intended to fund a single award. The National Institute on Aging is announcing its intent to issue a single source cooperative agreement award to Indiana University Indianapolis for the National Centralized Repository for Alzheimer's Disease and Related Dementias.
Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives Clinical Trials Not Allowed
(PAR-25-003)
Food and Drug Administration
The purpose of this Notice of Funding Opportunity (NOFO) is to advance efforts for a nationally integrated animal food safety system providing state animal food regulatory programs the ability to achieve full implementation of the Animal Food Regulatory Program Standards (AFRPS) within 5 years and to maintain full implementation. This NOFO will also fund optional projects for state animal food regulatory programs to:
- Advance food safety and protect public health by strengthening partnerships with the FDA and other state animal food regulatory partners through sharing, collaboration, coordination, and leveraging each other’s expertise, work, data, and enforcement actions.
- Develop and standardize processes, procedures, systems, and other methods to integrate federal and state animal food regulatory work resulting in mutual reliance.
Specific outcomes may include, but are not limited to:
- State animal food regulatory programs will achieve and maintain implementation of the AFRPS, which is recognized as a critical element to creating a national, fully integrated food safety system.
- Operational use of standardized animal food regulatory systems developed by state programs to compel federal reliance on state regulatory work and resources and reciprocal state reliance on federal work and resources, resulting in mutual reliance.
Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)
(RFA-AI-24-079)
National Institute of Allergy and Infectious Diseases
The purpose of this notice of funding opportunity (NOFO) is to invite applications from single institutions or consortia of institutions to participate in the Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program. The program will support centers that integrate clinical and translational research to conduct studies on the mechanisms underlying the onset and progression of diseases of interest, including asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overarching goal of the program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.
